Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.
LATEST PRESS RELEASES
Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands
Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...
Stayble has submitted applications to regulatory authorities in Spain for start of the Phase 2b clinical trial.
The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities in Sp...